European Journal of Cancer
Volume 37, Issue 4 , Pages 470-477 , March 2001

Prospective randomised study of split-course radiotherapy versus cisplatin plus split-course radiotherapy in inoperable squamous cell carcinoma of the oesophagus

  • Th. Wobbes

      Affiliations

    • Department of Surgery, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31-24-361-6421; fax: +31-24-354-0501
    • ,
  • B. Baron

      Affiliations

    • EORTC Data Center, Brussels, Belgium
    • ,
  • B. Paillot

      Affiliations

    • Hôpital Charles Nicolle, Rouen, France
    • ,
  • J.H. Jacob

      Affiliations

    • Centre Francois Baclesse, Caen, France
    • ,
  • P. Haegele

      Affiliations

    • Centre Paul Strauss, Strasbourg, France
    • ,
  • M. Gignoux

      Affiliations

    • Centre Hospitalier Universitaire, Caen, France
    • ,
  • P. Michel

      Affiliations

    • Hôpital Charles Nicolle, Rouen, France
    • ,
  • M-L. Couvreur

      Affiliations

    • EORTC Data Center, Brussels, Belgium

Received 12 November 1999 ,Revised 3 November 2000 ,Accepted 7 November 2000.

References 

  1. Perez CA, Stanley K, Rubin P, et al.  A prospective randomized study of various irradiation doses and fractionating schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Cancer. 1980;45:2744–2753
  2. Marcial VA, Pajak TF, Kramer S, et al.  Radiation Therapy Oncology Group (RTOG) studies in head and neck cancer. Semin. Oncol. 1988;15:39–60
  3. Levitt SH, Frazier AB, James KW. Split-course radiotherapy in the treatment of carcinoma of the esophagus. Radiology. 1970;94:433–435
  4. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958;53:457–481
  5. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 1966;50:163–170
  6. Cox DR. Regression models and life-tables. J. R. Stat. Soc. 1972;B34:187–202
  7. Kelsen DP, Ilson DH. Chemotherapy and combined-modality therapy for esophageal cancer. Chest. 1995;107:224S–232S
  8. Ajani JA. Contributions of chemotherapy in the treatment of carcinoma of the esophagus (results and commentary). Semin. Oncol. 1994;21:474–482
  9. Kok TC. Chemotherapy in esophageal cancer. Cancer Treat. Rev. 1997;23:65–85
  10. Bleiberg H, Conroy T, Paillot B, et al.  Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur. J. Cancer. 1997;33:1216–1220
  11. Douple EB, Richmont RC. Platinum complexes as radiosenzitizers of hypoxic mammalian cells. Br. J. Cancer. 1987;37:98–102
  12. Laverick M, Nias AHW. Potentiation of the radiation response of hypoxic mammalian cells by cis-dichlorobis(isopropylamine) trans-hydroxy platinum. Br. J. Radiol. 1981;54:529–534
  13. Kolarić K, Nagy B, Roth A, Županc D, Luetić J, Tometiċ Z. Combined cis-platinum plus radiation antitumor activity in locoregionally advanced squamous cell esophageal cancer. Oncology. 1988;45:276–280
  14. Cooper JS, Guo MD, Herskovic A, et al.  Chemoradiotherapy of locally advanced esophageal cancer. Long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA. 1999;281:1623–1627
  15. George SL. The required size and length of a phase III clinical trial. In Buyse ME, Staquet MJ, Sylvester RJ, eds. Cancer Clinical Trials Methods and Practice. Oxford Medical Publications, 1988, 382–406.
  16. Roussel A, Bleiberg H, Dalesio O, et al.  Palliative therapy of inoperable oesophageal carcinoma with radiotherapy and methotrexate (final results of a controlled clinical trial). Int. J. Radiat. Oncol. Biol. Phys. 1989;16:67–72

PII: S0959-8049(00)00399-3

European Journal of Cancer
Volume 37, Issue 4 , Pages 470-477 , March 2001

Article Tools

* Image Usage & Resolution